The gefitinib long-term responder (LTR)—A cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP)-Reference-Cited by-同舟云学术

The gefitinib long-term responder (LTR)—A cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP)

Published:2012-07 Issue:1 Volume:77 Page:183-191
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Gottschling Sandra,Herpel Esther,Eberhardt Wilfried E.E.,Heigener David F.,Fischer Jürgen R.,Köhne Claus-Henning,Kortsik Cornelius,Kuhnt Thomas,Muley Thomas,Meister Michael,Bischoff Helge G.,Klein Peter,Moldenhauer Ines,Schnabel Philipp A.,Thomas Michael,Penzel Roland

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference42 articles.

1. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer;Schiller;N Engl J Med,2002

2. Screening for epidermal growth factor receptor mutations in lung cancer;Rosell;N Engl J Med,2009

3. Gefitinib or carbopatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

4. Gefi tinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol,2010

5. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer;Hirsch;J Clin Oncol,2006

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study;Therapeutic Advances in Medical Oncology;2021-01

2. First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials;Lung Cancer;2019-07

3. Long-lasting response to afatinib that persisted after treatment discontinuation in a case ofEGFR-mutated lung adenocarcinoma;BMJ Case Reports;2019-01

4. Comparative Proteome Profiling and Mutant Protein Identification in Metastatic Prostate Cancer Cells by Quantitative Mass Spectrometry-based Proteogenomics;Cancer Genomics - Proteomics;2019

5. Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells;Stem Cells;2018-02-05